The treatment traditionally consists of a combination of medical and surgical treatment. Somatostatin analogues and Interferon decrease the secretion of hormones and the resulting symptoms. Radionuclide therapy with 177-Lutetium-DOTA-Octreotate increases progression-free survival. Traditionally, the primary tumor has been surgically removed even in the case of metastatic disease, although this was in 2017 shown not to improve survival in asymptomatic patients.
Small intestine neuroendocrine tumor
Pancreatic neuroendocrine tumor
Goblet cell carcinoid
Neuroendocrine tumor
VIPoma
Hereditary diffuse gastric cancer
Acinar cell carcinoma of the pancreas
Metastatic insulinoma